CCL11 and early-onset autosomal dominant Alzheimer disease: CCL11 is widely recognized as a biomarker of neuroinflammatory disorders, including multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and COVID-19–associated neurological syndromes [36], and warrants further investigation into its involvement in USUV-associated neuropathogenesis.